(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2012 (27.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/175741 A2

(51) International Patent Classification:
C07K 16/00 (2006.01)

(21) International Application Number:
PCT/EP2012/062251

(22) International Filing Date:
25 June 2012 (25.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/500,360	23 June 2011 (23.06.2011)	US
61/500,464	23 June 2011 (23.06.2011)	US
PCT/EP2011/067132	30 September 2011 (30.09.2011)	EP
61/541,368	30 September 2011 (30.09.2011)	US
13/435,567	30 March 2012 (30.03.2012)	US
PCT/EP2012/061304	14 June 2012 (14.06.2012)	EP

(71) Applicant *(for all designated States except US)*: **ABLYNX NV** [BE/BE]; Technologiepark 21, B-9052 Ghent-Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAUMEISTER, Judith** [DE/BE]; Nonnenstraat 8, B-2800 Mechelen (BE). **BOUCHE, Marie-Paule, Lucienne, Armanda** [BE/BE]; Braemstraat 66, B-9050 Gentbrugge (BE). **BOUTTON, Carlo** [BE/BE]; Rijksweg 115, B-8710 Wielsbeke (BE). **BUYSE, Marie-Ange** [BE/BE]; Burgemeester Edmond Ronsestraat 23, B-9820 Merelbeke (BE). **SNOECK, Veerle** [BE/BE]; Wannegemstraat 20, B-9750 Zingem (BE). **STAELENS, Stephanie** [BE/BE]; Normandiestaat 4, B-8560 Wevelgem (BE).

(74) Agents: **STEFFERL, Andreas** et al.; Hoffmann · Eitle, Arabellastrasse 4, 81925 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS

(57) **Abstract**: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; - methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; - modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

WO 2012/175741 A2